Vandalia Research
APDN Acquires Assets of DNA Manufacturer Vandalia Research | ADNAS.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
$1.5m Valuation: $1.5m | Acquisition | ||
| Total Funding | 000k | ||
Related Content
Vandalia Research Inc. operated as a specialized biotechnology firm focused on the large-scale production of high-purity DNA. The company originated as a spinoff from Marshall University in Huntington, West Virginia. Its business was centered around a proprietary, patented technology known as the Triathlon™ system. This system was engineered to mass-produce specific DNA sequences through an industrial-scale polymerase chain reaction (PCR) process. The primary benefit of this method was its ability to amplify DNA without the impurities associated with more common fermentation-based production, a critical quality advantage for medical applications.
The company catered to clients in the biotechnology, pharmaceutical, and diagnostic markets, providing DNA for use as business-critical reagents, therapeutics, and diagnostics. Revenue was generated through these contract production services. The Triathlon™ system's continuous flow method for heating and cooling PCR reagents allowed for processing significant volumes, moving DNA amplification from the lab bench to an industrial scale. This capability was crucial for producing the longer DNA sequences required for applications like gene therapy and DNA vaccines.
In September 2015, Vandalia Research was acquired by Applied DNA Sciences (APDN) for $1.5 million in cash. The acquisition included Vandalia's intellectual property, customer portfolio, and its physical assets, which were subsequently moved to APDN's headquarters in Long Island. This transaction was strategic for APDN, as it provided an entry into medical markets and created what was believed to be the world's largest capacity for bulk DNA manufacturing via PCR. Following the acquisition, Vandalia's former CEO and co-inventor of the Triathlon platform, Derek Gregg, joined APDN as a consultant to support the integration and sales efforts.
Keywords: DNA production, polymerase chain reaction, PCR manufacturing, Triathlon system, DNA amplification, custom DNA, gene therapy, DNA vaccines, diagnostic reagents, pharmaceutical reagents, biotechnology, Vandalia Research, Applied DNA Sciences, Derek Gregg, Marshall University spinoff, high-purity DNA, DNA synthesis, molecular diagnostics, biotherapeutics, large-scale DNA production